



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/760,588
				Filing Date	January 16, 2001
				First Named Inventor	Melton B. Affrime
				Art Unit	1614
				Examiner Name	C. Delacroix-Muirheid
				Attorney Docket Number	AL01132K
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
cm	A1	4,659,716	04/21/1987	Villani, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
cm	B2	WO 96/20708	07/11/1996	Sepracor, Inc.		
	B3	WO 01/21161 A2	03/29/2001	Schering Corp.		
	B4	WO 01/21162 A2	03/29/2001	Schering Corp.		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
cm	C1	W. KREUTNER, et al., <i>Preclinical Efficacy and Antiallergic Profile of Desloratadine, a Selective and Nonsedating Histamine H₁-Receptor Antagonist</i> (Abstract 1118), J. Allergy Clin. Immunol., Vol. 105, No. 1, part 2, pp. S382-383 (January 2000)	
	C2	L. M. SALMUN, et al., <i>Efficacy and Safety of Desloratadine in Seasonal Allergic Rhinitis</i> (Abstract 1123), J. Allergy Clin. Immunol., Vol. 105, No. 1, part 2, pp. S384-385 (January 2000)	
	C3	D. PADHI, et al., <i>Multiple-Dose Pharmacokinetics, Safety, and Tolerance of Desloratadine in Healthy Volunteers</i> (Abstract 1124), J. Allergy Clin. Immunol., Vol. 105, No. 1, part 2, pp. S385 (January 2000)	
	C4	J. M. HERRON, et al., <i>Dose-Proportionality, Linearity, and Pharmacokinetics of Desloratadine in Healthy Volunteers</i> (Abstract 1126), J. Allergy Clin. Immunol., Vol. 105, No. 1, part 2, pp. S385 (January 2000)	

Examiner Signature	cm	Date Considered	11/15/02
-----------------------	----	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ERROR! UNKNOWN DOCUMENT PROPERTY NAME.